Biopharmaceutical leader Kiniksa Pharmaceuticals (KNSA) is approaching a new buy point in the wake of a strong quarterly sales report. That makes Kiniksa stock Thursday's pick for IBD 50 Growth Stocks To Watch from Investor's Business Daily.
Kiniksa develops and commercializes medicines for cardiovascular, autoimmune and autoinflammatory diseases. Its only drug, Arcalyst, treats recurrent pericarditis, a condition in which the sac protecting the heart, the pericardium, becomes inflamed. The risk of recurrence increases with each subsequent flare-up of pericarditis, according to the Arcalyst website.
The company expects to replace Arcalyst with a next-generation version, now called KPL-387, in 2028 or 2029.
While Arcalyst requires a weekly under-the-skin shot, KPL-387 is a monthly injection. KPL-387 sales are expected to start slow at $21.7 million in 2028, growing to $173.7 million, $486.3 million and $1.03 billion over the next three years.
During the second quarter, Arcalyst generated $243.6 million in sales, growing 55% year over year. That crushed estimates from FactSet that called for $227.7 million.

#next #biopharmaceutical

With a market cap of $138.2 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines worldwide. Its portfolio spans key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, with well-known products such as Opdivo, Eliquis, Revlimid, and Yervoy.
Companies valued at $10 billion or more are generally classified as "large-cap" stocks, and Bristol-Myers Squibb fits this criterion perfectly. The company serves patients through a broad commercial network that includes wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies.
Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business'
Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable
A Potential ***** eX Deal Could Meaningfully Accelerate Growth for Technip Stock

#company #bristol #squibb #Stock

On August 26, Biohaven (NYSE:BHVN) and SK Biopharmaceuticals announced a global licensing agreement covering opakalim, Biohaven's lead epilepsy candidate, in a deal worth up to $795 million plus royalties. SK Biopharmaceuticals picks up exclusive worldwide rights to Biohaven's Kv7 ion channel platform, while Biohaven walks away with $400 million in near-term cash. The timing lines up with an August 10, 2026 earnings report that showed Biohaven still losing well over $100 million a quarter, and the gap between those two dates explains a lot about why this deal happened now.
SK Biopharmaceuticals will pay up to $795 million in upfront and milestone payments connected to the Kv7 platform, on top of tiered royalties on US net sales of opakalim that range from the mid-teens to low twenties. Biohaven collects $350 million at closing and another $50 million in 2027, with as much as $150 million more available through development and regulatory milestones plus royalties on global sales. SK Biopharmaceuticals is also taking over Kv7 program costs going forward, including certain Knopp Biosciences obligations. CEO Vlad Coric described the structure as proof Biohaven can monetize its pipeline through partnerships rather than leaning on public markets for cash.
The deal only makes sense because opakalim looks like it works. In a proof-of-concept study in idiopathic generalized epilepsy, the median time to a second generalized tonic-clonic seizure stretched to 141 days on opakalim versus 47 days on placebo, and a third of patients made it through the full 24 weeks without a second seizure. In focal epilepsy, 54% of patients in an open-label extension study saw at least a 50% drop in seizure frequency over any six months, in a group of more than 100 patients.
Opakalim is also designed as a once-daily pill with no ******* ration required, a real edge over older antiseizure drugs. Pairing that data with SK Biopharmaceuticals, the company behind XCOPRI and the only firm to bring a new focal-seizure drug to the US market since 2016, gives Opakalim a commercial path Biohaven would have struggled to build alone. The cash also buys runway for the rest of the pipeline, including protein degraders BHV-1300 and BHV-1400, which have shown rapid, selective reductions in disease-driving antibodies in Graves' disease and IgA nephropathy with clean safety data across nearly 200 patients dosed.
Biohaven is giving up full ownership of an ******* et it now believes could be a major seller. Royalties in the mid-teens to low twenties are real money, but they are a fraction of what outright ownership of an approved epilepsy drug would be worth, and $50 million of the $400 million upfront does not arrive until 2027. The Knopp Biosciences obligations SK Biopharmaceuticals is absorbing, worth up to $245 million plus mid-single-digit royalties, are a reminder that other parties already have claims on opakalim's future revenue before Biohaven sees a dollar of profit from it.

#ro

By Karen Roman
Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company).
Mr. Benecchi will lead the company's operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for the last quarter of 2026, and also prepare for potential commercialization, it stated.
"As we approach our Phase 3 readout, we are preparing the company for the next stage of its evolution," said Andrew Obenshain, Inventiva's CEO. "Chris brings a valuable combination of commercial, operational and launch experience, with a proven track record of helping organizations bring promising medicines to patients."
Mr. Benecchi has 30 years of biopharmaceutical leadership experience across commercial, operational and enterprise roles, with a record of building organizations, preparing investigational medicines for launch, and leading cross-functional execution in competitive and access-challenged markets, Inventiva said.

#chris #chief #commercial

North Chicago, Illinois-based AbbVie Inc. (ABBV) is a global, research-driven biopharmaceutical company focused on developing and commercializing medicines for complex and serious diseases. Valued at a market cap of $386.3 billion, its key therapeutic areas include immunology, neuroscience, oncology and aesthetics, with operations spanning more than 75 countries.
Companies with a market capitalization of $200 billion or more are typically referred to as "mega-cap stocks." ABBV fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the general drug manufacturers industry. AbbVie combines a large established pharmaceutical portfolio with a rapidly expanding immunology franchise and a broad pipeline.
Wu-Tang Clan Member Raekwon Is a Palantir 'OG,' Visiting Headquarters 16 Years After Receiving His Custom PLTR Jacket
Tesla Just Killed Its Solar Roof After Years of Struggling to Scale. What It Means for TSLA Stock.
Tesla Stock Could Benefit as Trump Locks Down the U.S. Power Grid

#abbvie #abbv #billion

Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global research-driven biopharmaceutical company focused on developing medicines, vaccines, and animal-health products. Known as MSD outside the U.S. and Canada, Merck operates through two main businesses: Pharmaceuticals and Animal Health. Valued at a market cap of $297 billion, its pharmaceutical portfolio spans oncology, vaccines, cardiometabolic disease, infectious diseases, and other therapeutic areas.
Companies with a market cap of $200 billion or more are typically referred to as "mega-cap stocks." It fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the general drug manufacturers industry. Merck combines a dominant oncology franchise, a broad vaccine portfolio, an expanding pipeline of newer medicines, and a large animal-health business. Its key investment consideration is balancing the continued strength of Keytruda and newer products against pressure on mature franchises such as Gardasil and the eventual impact of Keytruda's patent expiry.
Wu-Tang Clan Member Raekwon Is a Palantir 'OG,' Visiting Headquarters 16 Years After Receiving His Custom PLTR Jacket
Tesla Just Killed Its Solar Roof After Years of Struggling to Scale. What It Means for TSLA Stock.
Tesla Stock Could Benefit as Trump Locks Down the U.S. Power Grid

#animal #medicines #products

Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, alongside a proactive stance on profit-taking. The focus will remain on owning strong businesses and conducting research that challenges consensus views, as several major investments are poised for significant events within the year. Despite declines in market multiples, underlying businesses continue to grow, suggesting a favorable positioning for returns. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted Liquidia Corporation (NASDAQ:LQDA). Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company, focusing on developing therapies for rare cardiopulmonary diseases. On August 14, 2026, Liquidia Corporation (NASDAQ:LQDA) closed at $74.44 per share. One-month return of Liquidia Corporation (NASDAQ:LQDA) was 0.26% and its shares gained 178.79% over the past 52 weeks. Liquidia Corporation (NASDAQ:LQDA) has a market capitalization of $6.66 billion.
Greenhaven Road Capital stated the following regarding Liquidia Corporation (NASDAQ:LQDA) in its Q2 2026 investor letter:
"Liquidia Corporation (NASDAQ:LQDA) — This is another special situation. The company has launched a successful drug but remains in a patent dispute that will determine how large their market can be. We purchased shares below where I believed they would settle even after an adverse trial outcome. The shares appreciated more than 30% before a verdict, so we realized a short-term gain and will revisit the investment after the decision."
Liquidia Corporation (NASDAQ:LQDA) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held Liquidia Corporation (NASDAQ:LQDA) at the end of the first quarter which was 44 in the previous quarter. While we acknowledge the potential of Liquidia Corporation (NASDAQ:LQDA) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

#corporation

Aspire Biopharma Holdings Inc. (NASDAQ:ASBP) said Monday it completed its $30 million acquisition of Dura Driver Control Systems, expanding the biopharmaceutical company into the automotive and mobility-control market.
The deal, first announced in June, gives Aspire 100% ownership of Dura Driver Control Systems, or DCS, which is now a wholly owned subsidiary. Aspire paid about $30 million in cash.
DCS is a tier-one automotive supplier focused on electronic driver controls and systems supporting vehicle electrification, safety, lightweighting and sustainability. Aspire said the acquisition is expected to add revenue, earnings and cash flow while diversifying its business.
The company also entered into a $22.5 million senior secured revolving credit facility in connection with the transaction. The company said it will use borrowings from the facility, along with cash on hand, to finance the acquisition.
"Closing the DCS acquisition is a cash-flow-positive milestone that structurally enhances Aspire's valuation," CEO and Board Chair Kraig Higginson said.

#aspire #company

Interested in Zai Lab Limited Unsponsored ADR? Here are five stocks we like better.
Q2 net product revenue rose 11% sequentially to $105.8 million, supported by VYVGART volume growth, steady ZEJULA sales, XACDURO strength and the early KarXT launch. Management expects revenue to stabilize in late 2026 before returning to meaningful year-over-year growth in 2027, with $717.5 million in cash at quarter-end.
Zoci development is expanding toward potential U.S. approval. Zai Lab expects three registrational programs by the end of 2026, plans to complete a Phase III small-cell lung cancer enrollment in the first half of 2027 and anticipates a possible accelerated-approval filing later that year, with potential approval in 2028.
The company continues advancing its global pipeline, including ZL-1503 for atopic dermatitis, ZL-6201 for solid tumors and ZL-1311 for gastrointestinal cancers. Zai Lab also expects its first U.S. regulatory submission next year as it transitions from a China-focused business into a global biopharmaceutical company.
Zai Lab Stock Has Fallen to Value Levels

#expects #Potential #global

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund's outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund's top five holdings to know the best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Gilead Sciences, Inc. (NASDAQ:GILD). Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs, detracted from the fund's performance during the quarter. On August 03, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) closed at $131.15 per share. The one-month return of Gilead Sciences, Inc. (NASDAQ:GILD) was -3.82%, and its shares gained 16.62% over the past 52 weeks. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $162.83 billion.
Baron Health Care Fund stated the following regarding Gilead Sciences, Inc. (NASDAQ:GILD) in its Q2 2026 investor letter:
"Biotechnology company Gilead Sciences, Inc. (NASDAQ:GILD) is best known for developing and commercializing therapies that treat and prevent HIV. Following a strong first-quarter advance driven by continued enthusiasm surrounding the launch of Yeztugo for HIV prevention, the stock detracted from performance in the second quarter. Shares pulled back after management issued conservative 2026 guidance in February, including expectations for approximately $800 million of Yeztugo sales, below investor expectations. Despite the more cautious outlook, we remain confident in Yeztugo's long-term opportunity. Unlike Descovy, a daily oral preventive treatment, Yeztugo is a twice-yearly injectable therapy that has the potential to significantly improve patient compliance. Looking ahead, we continue to view Gilead as a leader in HIV treatment and prevention, with Yeztugo representing an important new preventive option and a promising next-generation pipeline that includes a weekly oral lenacapavir and islatravir combination being developed with Merck & Co., Inc., as well as a wholly-owned weekly regimen incorporating a novel integrase inhibitor designed to offer a higher barrier to resistance."

#sciences #gild #Health

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund's outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund's top five holdings to know the best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Veradermics, Incorporated (NYSE:MANE). Veradermics, Incorporated (NYSE:MANE), a clinical-stage biopharmaceutical company developing treatments for pattern hair loss in adults and children, contributed to the Fund's performance during the quarter. On August 03, 2026, Veradermics, Incorporated (NYSE:MANE) closed at $101.89 per share. The one-month return of Veradermics, Incorporated (NYSE:MANE) was -13.05%. Veradermics, Incorporated (NYSE:MANE) has a market capitalization of $4.26 billion.
Baron Health Care Fund stated the following regarding Veradermics, Incorporated (NYSE:MANE) in its Q2 2026 investor letter:
"Veradermics, Incorporated (NYSE:MANE), a dermatologist founded, late clinical-stage biopharmaceutical company developing VDPHL01, an extended-release oral minoxidil tablet for pattern hair loss. In April, the company reported solid Phase 3 data in male pattern hair loss. The drug demonstrated robust hair growth with up to 63% of male patients reporting improved hair coverage compared to just 13% on placebo. We await data from a second Phase 3 study of VDPHL01 in male pattern hair loss and the first clinical data from a Phase 2 study of VDPHL01 in female pattern hair loss patients, both expected in the second half of 2026. If VDPHL01 is U.S. Food and Drug Administration (FDA) approved, we think it will be uniquely positioned as the first FDA-approved oral treatment in several decades for a condition affecting 80 million Americans."

#incorporated #vdphl01

This has been an active year in the mergers-and-acquisitions landscape across the biopharmaceutical industry. One of the more notable deals was Vertex Pharmaceuticals' acquisition of Crinetics Pharmaceuticals for $10 billion in cash (the transaction hasn't closed yet). This is the largest acquisition in Vertex Pharmaceuticals' history, and it will enable the biotech giant to gain several promising pipeline candidates in endocrinology. Could there be an even more massive acquisition on the horizon in the industry? It's hard to say for sure, but if there is, Viking Therapeutics (NASDAQ: VKTX) may be the acquisition target.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
According to the U.S. Centers for Disease Control and Prevention, a little over 70% of adults in the country are overweight or obese. Excess weight is linked to a range of serious health problems, including diabetes, heart disease, and many others. Recent breakthroughs are helping address the issue. Anti-obesity medicines are allowing patients to lose weight and reduce their risk of developing a range of conditions. But this market is still in its early stages and is projected to expand rapidly over the next decade. According to some estimates, it will be worth $190 billion in 2035, compared to just $79 billion last year.
No wonder, then, that many pharmaceutical giants are looking to dip their toes in this **** e. But discovering and developing brand-new therapies from scratch in any field is expensive and time-consuming. That's why well-established drugmakers often prefer to acquire companies with promising mid and late-stage **** ets. That's where Viking Therapeutics comes in. The company's portfolio includes subcutaneous VK2735, currently in phase 3 clinical trials, as well as an oral version of the drug, which should begin late-stage studies by year-end. Further, Viking Therapeutics developed VK3019, another weight-loss candidate, which recently started phase 1 clinical trials.
Viking Therapeutics has one of the more impressive weight-loss pipelines among mid-cap biotechs, making it a great target for a pharmaceutical leader looking to fast-track the process and land some highly promising anti-obesity pipeline candidates overnight. Viking Therapeutics' phase 3 studies for VK2735 are expected to be completed by late 2027. If the results are very strong, the company's shares will soar, making it a much more expensive acquisition target. So, if any pharmaceutical giant is going to make a move, it probably will be before then.

#viking #NVIDIA #weight #promising

Carillon Tower Advisers, an investment management company, released its second-quarter 2026 investor letter for the "Carillon Eagle Mid Cap Growth Fund". A copy of the letter is available to download here. Mid-cap stocks delivered strong results, with the Russell Midcap® Growth Index rising 14.55% and slightly outperforming the Russell Midcap® Value Index's 13.40% gain. Information technology led the growth index with a 36.90% return, while industrials also outperformed, and energy was the only sector to decline. The quarter was supported by resilient corporate earnings, economic growth and AI infrastructure spending, although geopolitical tensions, higher energy prices and election-related uncertainty could create volatility. The firm remains optimistic that data-center investment will support technology, energy, defense and automation companies, while attractive healthcare valuations and stronger merger activity could create opportunities. However, financials and consumer stocks face mixed conditions because of housing weakness, inflation and uneven spending. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its second-quarter 2026 investor letter, Carillon Eagle Mid Cap Growth Fund highlighted Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company focusing on developing therapies for patients with serious and rare diseases. On July 23, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $103.12 per share, reflecting a market capitalization of $22.35 billion. Insmed Incorporated (NASDAQ:INSM) posted a one-month return of -10.60%, and its shares lost 7.00% over the past 52 weeks.
Carillon Eagle Mid Cap Growth Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor letter:
"Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company underperformed primarily because first-quarter Brinsupri sales, which were ahead of consensus estimates, fell short of more bullish estimates. Fortunately, second-quarter prescription trends have been strong and point to sales closer to the high end of consensus expectations."
Insmed Incorporated (NASDAQ:INSM) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 67 hedge fund portfolios held Insmed Incorporated (NASDAQ:INSM) at the end of the first quarter which was 75 in the previous quarter. While we acknowledge the potential of Insmed Incorporated (NASDAQ:INSM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

#insmed #company

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. With a market cap of $129.9 billion, the company offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.
Shares of BMY have rallied the broader market over the past year, surging 33.9% compared to the S&P 500 Index's ($SPX) 16.3% surge. Moreover, in 2026, the stock has risen by nearly 17.9%, outpacing the SPX's 8.5% gain.
Dear Sandisk Stock Fans, Mark Your Calendars for August 5
Nasdaq Futures Plunge as Chip Selloff Rages On, FOMC Meeting and Earnings on Tap
Ahead of Microsoft Earnings, Here's What Barchart Data Says Comes Next for MSFT Stock

#products #bristol #squibb

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
Sarepta Therapeutics has found the leader it hopes can engineer a desperately needed turnaround.
The company on Monday announced that Michael Severino, an executive with leadership experience at startups as well as large drugmakers, will become its next CEO effective July 28. He'll replace longtime leader Doug Ingram, who in February announced plans to retire after a tumultuous run.
Severino has been working in the biopharmaceutical industry for more than two decades, including stops at AbbVie and Amgen. At AbbVie, Severino helped bring to market multiple drugs for psoriasis, arthritis, cancer and hepatitis C. At Amgen, he oversaw research and development as the company's senior vice president of development and corporate chief medical officer.
In 2022, Severino left AbbVie to run Tessera Therapeutics, a buzzy "gene writing" startup backed by Flagship Pioneering. Tessera recently brought its first drug prospect, a gene editing treatment for alpha-1 antitrypsin deficiency, into clinical testing. Last week, Tessera announced that Severino had joined a "commercial stage" biotech company and that former Merck & Co. executive Joseph Romanelli would serve as its next leader.

#abbvie #tessera #biopharma #amgen

If you're keeping an eye on gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP), you probably already know the up-and-coming biopharmaceutical outfit is a favorite of Ark Investment Management's CEO and chief stock picker, Cathie Wood. As of the latest look, the company's holding nearly $270 million worth of this name in its flagship Ark Innovation ETF (NYSEMKT: ARKK) and another $92 million worth in the smaller Ark Genomic Revolution ETF (NYSEMKT: ARKG).
What is surprising is why Wood is holding it. Although patient-specific genomic repair remains a key part of this stock's bullish thesis, CRISPR Therapeutics' developmental work on another front has gone largely unnoticed and may not be reflected in the stock's price.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
CRISPR Therapeutics' founders essentially found a way of repairing damaged DNA with a corrected genetic sequence. It was the first company to ever win the FDA's approval for a gene-editing drug, in fact. That's Casgevy -- for the treatment of sickle cell disease -- which was approved in late 2023. Now the same patient-specific approach is being tested as a therapy for handful of other genetic diseases.
The underlying science, however, isn't limited to a customized therapy for each patient. Gene editing can be used to create off-the-shelf treatments for all patients with a particular disease.

#editing

Fred Alger Management, an investment management company, released its "Alger Small Cap Focus Fund" second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States and Iran and accelerated investment in artificial intelligence (AI) fueled market optimism in the quarter, driving the Information Technology and Industrials sectors forward while Energy and Utilities lagged due to falling oil and gas prices. In June, the Federal Reserve maintained steady interest rates, but the meeting had a hawkish tone. As AI transitions into its agentic phase, opportunities are identified within sectors adopting the technology. The Alger Small Cap Focus Fund's Class A shares outperformed the Russell 2000 Growth Index in the quarter, driven by strong performances in the Industrials and Health Care sectors, while Financials and Consumer Discretionary detracted from the performance. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Alger Small Cap Focus Fund highlighted Forte Biosciences, Inc. (NASDAQ:FBRX). Forte Biosciences, Inc. (NASDAQ:FBRX), a US-based clinical-stage biopharmaceutical company, detracted from the Fund's performance during the quarter. On July 20, 2026, Forte Biosciences, Inc. (NASDAQ:FBRX) closed at $47.49 per share, reflecting a market capitalization of $972.54 million. Forte Biosciences, Inc. (NASDAQ:FBRX) posted a one-month return of 161.65%, while its shares gained 355.32% over the past 52 weeks.
Alger Small Cap Focus Fund stated the following regarding Forte Biosciences, Inc. (NASDAQ:FBRX) in its Q2 2026 investor update:
"Forte Biosciences, Inc. (NASDAQ:FBRX) is a clinical-stage biopharmaceutical company developing FB102, an anti-CD122 monoclonal antibody with potential application across a range of autoimmune conditions, including celiac disease, vitiligo, and alopecia areata. We view Forte favorably given the differentiated mechanism underlying FB102 and its potential applicability across multiple sizeable indications, supported by encouraging early celiac data and a series of meaningful clinical readouts anticipated through the balance of the year. Shares detracted from performance during the quarter, pressured by an equity raise whose limited initial disclosure was poorly received, as well as by growing investor impatience as anticipated vitiligo data extended beyond the previously communicated timeline. Despite a challenging quarter, we remain constructive ahead of the celiac readout expected later this year and cautiously optimistic on the forthcoming vitiligo results. We believe FB102 retains meaningful strategic value as its clinical profile comes into clearer focus."

#forte #biosciences #small #investor

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $166.7 billion by market cap, the company's primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions. The HIV giant is expected to announce its fiscal second-quarter earnings for 2026 in the near term.
Ahead of the event, ******* ysts expect GILD to report a loss of $7.09 per share on a diluted basis, down 452.7% from a profit of $2.01 per share in the year-ago quarter. The company has consistently surpassed the consensus estimates in each of the last four quarters.
Huge, Unusual Intel Options Volume Today Ahead of Earnings This Week
Intel Stock Is Down, But Put Premiums are High - Put Short Sellers Love the High Yields
The Number Tesla Stock Bulls Are Really Waiting for This Earnings Season Has Nothing to Do With Cars

#earnings

Fred Alger Management, an investment management company, released its "Alger Mid Cap Focus Fund" second-quarter 2026 investor letter. A copy of the letter can be downloaded here. US equities strongly rebounded in the second quarter, with the S&P 500 Index returning 15.2%. A ceasefire between the United States and Iran and accelerated investment in artificial intelligence (AI) fueled market optimism in the quarter, driving the Information Technology and Industrials sectors forward, while Energy and Utilities lagged due to falling oil and gas prices. Despite discussions about AI disruption, opportunities are identified within sectors adopting the technology as it enters its agentic phase. The Alger Mid Cap Focus Fund's Class A shares outperformed the Russell Midcap Growth Index in the quarter, driven by strong performances in Information Technology and Health Care, while Communication Services and Consumer Discretionary detracted from the performance. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Alger Mid Cap Focus Fund highlighted Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company focusing on developing therapies for patients with serious and rare diseases. On July 17, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $108.32 per share, reflecting a market capitalization of $23.49 billion. Insmed Incorporated (NASDAQ:INSM) posted a one-month return of 9.85%, and its shares gained 5.39% over the past 52 weeks.
Alger Mid Cap Focus Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor update:
"Insmed Incorporated (NASDAQ:INSM), GFL Environmental Inc, and Karman Holdings Inc. were among the top detractors from performance. Insmed is a commercial-stage biopharmaceutical company focused on respiratory, inflammatory, pulmonary, and rare disease treatments, with an approved portfolio that includes Brinsupri and Arikayce. The company's opportunity is tied to expanding adoption of its commercial products while advancing a pipeline aimed at areas of meaningful unmet medical need. During the quarter, shares detracted from performance despite headline results that were generally better than expected, as investors focused on early launch dynamics for Brinsupri. Concerns centered on patient additions, discontinuation rates, and compliance trends, which raised questions about the quality and durability of the launch. While these issues pressured the stock, management has begun providing greater detail around launch dynamics, and we believe improved execution and additional data could help restore investor confidence over time."

#insmed #incorporated #focus #technology

AtaiBeckley (NASDAQ:ATAI), a clinical-stage mental health and psychedelic drug developer, closed at $7.15, up 33.4%. Eli Lilly's (NYSE:LLY) announced acquisition drove the move, and investors are watching the deal terms and closing process. Trading volume reached 164.9M shares, coming in about 1,494% above its three-month average of 10.3M shares. AtaiBeckley IPO'd in 2021 and has fallen 64% since going public.
The S&P 500 (SNPINDEX:^GSPC) fell 0.50% to 7,535, and the Nasdaq Composite (NASDAQINDEX:^IXIC) fell 1.47% to 25,882. Among clinical-stage biopharmaceuticals focused on mental health and psychedelic therapeutics, COMPASS Pathways (NASDAQ:CMPS) fell 6.61% to $12.43, while broader psychedelics sentiment stayed tied to AtaiBeckley's Lilly deal.
Pharmaceutical behemoth Eli Lilly acquired AtaiBeckley in a purchase worth up to $3.8 billion today, sending the latter's shares 34% higher. The deal consists of $6.75 in cash per ATAI share, as well as $2.50 in contingent value rights (CVRs) tied to two of AtaiBeckley's treatments meeting certain milestones over the next four, five, and seven years.
Thanks to the value of these CVRs, ATAI's $7.15 share price currently sits above the $6.75 cash portion of the deal, suggesting the market sees potential in AtaiBeckley's psychedelic treatments reaching their various milestones. AtaiBeckley offers DMT and other psychedelic treatments for depression, anxiety, and opioid use disorder, and has seen its stock double over the last year thanks to today's deal and the Trump administration's positive outlook on psychedelic-based treatments.
Before you buy stock in AtaiBeckley, consider this:

Pfizer Inc. (NYSE:PFE) is one of the 8 Worst Blue Chip Stocks to Buy Now.
On July 10, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer, regardless of cisplatin eligibility. Pfizer said this marks the first platinum-free regimen approved for adult patients with MIBC, regardless of cisplatin eligibility.
The approval was based on results from the pivotal Phase 3 EV-304 clinical trial, which were presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium. The expanded indication builds on the November 2025 U.S. FDA approval of the combination for use as neoadjuvant and adjuvant treatment in cisplatin-ineligible adult patients with MIBC, based on results from the EV-303 Phase 3 clinical trial published in the New England Journal of Medicine.
Also on July 10, BofA lowered the firm's price target on Pfizer to $26 from $27 and kept a Neutral rating on the shares. On July 6, HSBC downgraded Pfizer to Hold from Buy with a price target of $28, down from $32. HSBC lowered its view of the probability to market of sigvotatug vedotin to 40% following the Phase 3 setback in NSCLC and said it is now "less convinced" regarding short-term re-rating potential due to recent executive management changes and "a paucity of short-term re-rating catalysts."
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the 8 Most Undervalued Growth Stocks to Buy for the Next 10 Years. On June 16, H.C. Wainwright ******* yst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics Inc. (NASDAQ:HALO) and ******* igned a target price of $95. The stock's potential has been noticed by market participants, as evident from the 46% rise in the last 12 months. With earnings growth expected to continue, HALO is one of our most undervalued growth stocks to buy for the next 10 years.
On a more positive front, on June 13, Johnson & Johnson announced that Halozyme-partnered Darzalex Faspro, when used with its cancer drug Talvey, significantly improved survival outcomes in a late-stage trial for patients with multiple myeloma. The combination reduced the risk of death by up to 53% compared with the standard treatment. Darzalex Faspro is a front-line multiple myeloma therapy. The combination of two drugs, after about two years of follow-up, reduced the risk of cancer worsening or death by up to 72%. Additionally, at 24 months, about 89% of patients were alive, compared with 79% of those receiving standard care. The positive trial results could benefit HALO by supporting continued adoption of Darzalex Faspro, which uses the company's ENHANZE technology.
Halozyme Therapeutics Inc. (NASDAQ:HALO) is a biopharmaceutical company. It researches, develops, and commercializes proprietary enzymes and devices. The company's products are based on the patented recombinant human hyaluronidase enzyme that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules. The company was founded in 1998 and is headquartered in San Diego, California.
While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best AI Stocks to Watch in July and 12 Best Dow Stocks to Invest In Right Now.

Harris Oakmark recently released its second-quarter 2026 investor letter for the "Oakmark Global Fund". A copy of the letter can be downloaded here. It is a non-diversified fund that focuses on long-term capital appreciation by investing in common stocks of U.S. and non-U.S. companies. In the second quarter, the fund (Investor Class) delivered a return of 7.89%, lagging the benchmark, the MSCI World Index's 13.76% return. Energy and industrials were the top performance contributors at the sector level, while health care and consumer discretionary detracted from performance. AI remains a key market theme. The firm focuses on evaluating companies based on their competitive advantages, long-term cash flow potential, and valuation, not predictions. In addition, you can check the Fund's top five holdings to determine its best picks for 2026.
In its Q2 2026 investor letter, Oakmark Global Fund highlighted AstraZeneca PLC (NYSE:AZN) as a newly added position. AstraZeneca PLC (NYSE:AZN) is a leading multinational biopharmaceutical company focusing on the development and discovery of prescription medicines. On July 15, 2026, AstraZeneca PLC (NYSE:AZN) closed at $168.37 per share, reflecting a market capitalization of $261.12 billion. AstraZeneca PLC (NYSE:AZN) posted a one-month return of -3.75%, while its shares gained 18.55% over the past 52 weeks.
Oakmark Global Fund stated the following regarding AstraZeneca PLC (NYSE:AZN) in its Q2 2026 investor update:
"AstraZeneca PLC (NYSE:AZN) is one of the largest pharmaceutical companies in the world. It researches, develops and commercializes prescription medicines designed to treat lung and breast cancers, cardiorenal diseases, respiratory problems and other rare diseases. We believe AstraZeneca's robust on-market portfolio and sector-leading late-stage pipeline provide an attractive growth profile. Moreover, we believe the company can build on its long track record of a productive research and development program, thanks to its innovative culture and exceptional management team. In our view, CEO Pascal Soriot is one of the industry's best executives, and he has cultivated a deep bench of talent, a robust decision-making framework and a differentiated R&D culture that should drive strong growth for years to come, in our view. Recent concerns over United States regulations have overshadowed AstraZeneca's merits and weighed on the broader pharmaceutical industry. This opened a window for us to purchase shares of this company at a price well below our estimate of its intrinsic value."

Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors.
It was just another manic market day, at least for AstraZeneca.
Shares of the British-Swedish biopharmaceutical company tumbled Thursday after it shared the surprising failure of its drug Wainua to meet its target in a recent clinical trial. AstraZeneca and Ionis Pharmaceuticals said the heart disease treatment didn't outperform the placebo in preventing heart problems in patients with transthyretin-mediated amyloid cardiomyopathy (or ATTR-CM), a rare and potentially fatal disease.
It was a blow ***** ysts weren't expecting, and AstraZeneca's shares fell as much as 10.6% in London, its largest intraday plummet since 2017, per Bloomberg. The company's New York Stock Exchange-listed shares ended Thursday down 5.7%.
Sign up for The Daily Upside at no cost for premium ***** ysis on all your favorite stocks.

MannKind Corporation (NASDAQ:MNKD) is one of the Best Penny Stocks to Invest In According to Billionaires. MannKind Corporation (NASDAQ:MNKD) has gained roughly 20% since the FDA approved Afrezza, which is an inhaled insulin for children and adolescents aged 6 and older with type 1 or type 2 diabetes. The news came on May 29.
Management noted that this approval expands Afrezza beyond adults, where it was already approved. More than 350,000 children and adolescents in the US have diabetes, and most need lifelong insulin therapy. The drug works through the company's Technosphere platform, delivering insulin via the lungs for rapid absorption. Moreover, the approval was based on the INHALE-1 trial plus two decades of additional safety and efficacy data on inhaled insulin.
More recently, on June 23, MannKind Corporation (NASDAQ:MNKD) also announced receiving a grant from Breakthrough T1D to support the company's INHALE-1ST clinical study. The trial tests whether Afrezza can be used soon after a type 1 diabetes diagnosis in kids. The company's CEO called the partnership a sign of growing confidence in inhaled insulin's potential for newly diagnosed children.
Moreover, the Street is also bullish on the stock, with ***** ysts' 12-month average price target suggesting more than 54% upside from the current level.
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that specializes in chronic disease care. Incorporated in 1991, the company provides solutions for serious conditions, such as diabetes, pulmonary hypertension, and fluid overload.

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best healthcare stocks on our list.
TheFly reported on July 2 that UBS ******* yst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The ******* yst noted that the stock's 44% decline since mid-January presents an appealing opportunity for investors. UBS highlighted CRNX's pipeline as having multiple potential catalysts, supported by programs with strong chances of clinical success. The firm expressed the highest confidence in the Phase 3 atumelnant program for congenital adrenal hyperplasia and projects peak sales potential of approximately $2.0 billion.
In other news, on July 6, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, representing an equity value of approximately $10 billion, or about $8.8 billion after accounting for estimated acquired cash. The transaction received unanimous approval from both companies' boards and is expected to close in the third quarter of 2026. Vertex stated that CRNX's endocrine-focused portfolio, including PALSONIFY and atumelnant, aligns with its strategy of developing transformative medicines for diseases with significant unmet needs. The acquisition is expected to support Vertex's revenue growth, with the combined ******* ets projected to provide more than $5 billion in potential peak annual revenue.
Crinteics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company focused on developing oral, non-peptide therapies for endocrine diseases and tumors by targeting G-protein-coupled receptors (GPCRs). Its key programs include PALSONIFY (paltusotine), an FDA- and EMA-approved oral treatment for acromegaly; atremelnant, a Phase 3 therapy for congenital adrenal hyperplasia and Cushing's syndrome; and a pipeline targeting conditions such as Graves' disease, obesity, and other endocrine disorders, and this is what makes the company innovative.
While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

When it comes to dividend stocks, no other sector has been more reliable than the healthcare sector. No matter the economic scenario, there will always be demand for drugs treating life-threatening diseases. This keeps the sector defensive, allowing large pharmaceutical companies to generate steady cash flow and consistently reward shareholders.
Two pharmaceutical giants — AbbVie (ABBV) and Eli Lilly (LLY) — stand out for some of the fastest-growing drug portfolios in the industry. However, only one is the better choice for income-seeking investors. Let's take a closer look.
Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, ******* ysis, and headlines.
AbbVie is a global biopharmaceutical company that develops medicines for immunology, cancer, neuroscience, and aesthetics, with blockbuster drugs including Skyrizi, Rinvoq, and Botox. AbbVie's forward dividend yield of 2.65% is higher than the market and the healthcare sector average. This higher income compounds meaningfully over a decade, especially for investors who reinvest their dividends.
When AbbVie's top-selling drug, Humira, began losing patent protection, investors questioned whether it would weaken earnings and pressure dividends. However, the company has spent the last few years successfully replacing it, as Skyrizi and Rinvoq have become AbbVie's new growth engines, generating $6.6 billion in combined revenue in the first quarter of 2026.

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 8 Hidden Multibagger Stocks to Buy Now. During the last few trading sessions, Mineralys Therapeutics Inc. (NASDAQ:MLYS) has seen positive momentum. On June 4, Goldman Sachs **** yst Richard Law reiterated a Buy rating on the stock and **** igned a target price of $42.
Earlier on June 2, MLYS revised its agreement with Tanabe Pharma to gain full worldwide rights to lorundrostat without having to pay future royalties. Under this amendment, the company agreed to pay Tanabe a $200 million upfront cash payment and could make additional payments of up to $365 million if certain commercial targets are achieved. Moreover, the company secured a loan of up to $500 million from funds managed by Pharmakon Advisors. The financing will be provided in stages, with access to additional funds tied to the FDA approval of lorundrostat and the achievement of certain sales milestones. This loan will provide capital to support the company's growth and commercialization plans. However, it also increases MLYS's debt obligations, which could limit the company's financial flexibility.
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is a biopharmaceutical company that develops medicines to target diseases driven by dysregulated aldosterone. Its primary drug candidate is lorundrostat, which is used for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
While we acknowledge the potential of MLYS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Bitcoin Miners That Are Now Data Center Companies and Iran Peace Deal Sends Oil Lower: Top 8 Travel Stocks to Buy Now.

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 7, Cantor Fitzgerald ******* yst Prakhar Agrawal reiterated a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) and set a price target of $101. The firm's price target implies an additional 95% upside from current levels.
In addition to Prakhar Agrawal, BMO Capital ******* yst Evan Seigerman reiterated a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) on June 5 and set a target price of $145. The ******* yst believes that the company's most advanced weight-loss drug, aleniglipron, showed strong results in clinical trials. The data showed significant and sustained weight loss, along with a favorable safety profile with no major liver concerns. These positive results suggest aleniglipron could become one of the leading oral obesity treatments on the market.
In addition to weight loss, the drug showed benefits such as lowering blood pressure and reducing inflammation without causing a significant increase in heart rate. Evan Seigerman believes these results highlight the drug's broader health benefits. As the demand for obesity treatment grows, aleniglipron has the potential to become an attractive option due to its oral administration and lower-cost alternative to injectables.
Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage global biopharmaceutical company that develops and delivers novel oral small-molecule therapeutics. It treats various chronic diseases with unmet medical needs. The company was formerly known as ShouTi Inc. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the stock.
This update comes after AbbVie announced that it is acquiring Apogee Therapeutics. AbbVie said that it has entered into a definitive agreement to acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma.
Apogee's pipeline includes zumilokibart (APG777), a lead **** et. It is a subcutaneous half-life extended monoclonal antibody that targets IL-13 and is being developed as a treatment for atopic dermatitis. The company is also developing APG273, a combination of zumilokibart and APG333, an anti-TSLP half-life extended monoclonal antibody, for the treatment of asthma.
H.C. Wainwright noted that both Apogee and Oruka Therapeutics, Inc. (NASDAQ:ORKA) were created by privately-held Paragon Therapeutics and share several similarities. The firm said both companies focus on developing treatments for inflammatory and immune-related diseases, with a particular emphasis on inflammatory skin conditions.
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a biopharmaceutical company focused on developing novel biologics for the treatment of chronic skin diseases.